Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:
November 10th, 2013

Crohn’s Disease Activity Index (CDAI) & Patients with Irritable Bowel Syndrome (IBS)

By Brent Westra

Note: This post was originally published on Mayo Clinic's Advancing the Science blog on April 30, 2013

Edward Loftus Jr., M.D., a gastroenterologist at Mayo Clinic specializing in the care and evaluation of patients with IBD, discusses the implications of recent article published in Alimentary Pharmacology & Therapeutics that found a group of patients with IBS to have higher CDAI scores than patients with Crohn’s disease.

Specifically, Dr. Loftus mentions:

  •  Because signs of Crohn’s disease are neither sensitive nor specific, clinicians can’t rely on symptoms alone to make treatment decisions.
  • It is important to support the CDAI score with endoscopic measures, CRP levels, or measure of inflammation in the stool.

For more information on IBD, visit: mayoclinic.org/IBD

 

Tags: Alimentary Pharmacology & Therapeutics, CDAI, Edward Loftus, IBS, Study Findings

Comment

Please login or register to post a comment.
Contact Us · Privacy Policy